Hepatotoxicity Clinical Trial
Official title:
The Application of the N-acetyltransferase 2 (NAT2) Genotyping in Re-challenge Protocol of Isoniazid (INH) Titration in Patients With Anti-TB Medications-induced Hepatitis
To improve the treatment outcome in patients with tuberculosis and integrate the pharmacogenetics into clinical practice, the information of NAT2 genotyping was used in re-challenge protocol for isoniazid (INH) titration in patients with anti-tuberculosis medication-induced hepatitis.
n/a
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00137059 -
Acetaminophen-induced Hepatotoxicity in Chronic Alcohol Abusers
|
N/A | |
| Not yet recruiting |
NCT06251232 -
Proof-of-concept to Evaluate the Efficacy and Safety of Prednisone in Idiosyncratic Hepatotoxicity
|
Phase 2 | |
| Recruiting |
NCT05501899 -
Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia
|
Early Phase 1 | |
| Recruiting |
NCT00728546 -
NAT2 in Re-challenge of INH in Patients With Hepatitis
|
Phase 4 | |
| Recruiting |
NCT04635111 -
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
|
||
| Completed |
NCT03833297 -
Monitoring the HePAtological TOXicity of Drugs (HePATOX)
|
||
| Recruiting |
NCT03602274 -
APAP Hepatotoxicity After Therapeutic Doses
|
||
| Completed |
NCT00768716 -
Effect of Race/Ethnicity and Genes on Acetaminophen Pharmacokinetics
|
Phase 4 |